My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 100

    1.

    Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

    Lai TY, Lee GK, Chan WM, Lam DS.

    Br J Ophthalmol. 2006 Feb;90(2):243-4. No abstract available. PMID: 16424543 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of desferoxamine on retinal and visual function.

    Lu M, Hansen RM, Cunningham MJ, Eklund SE, Fulton AB.

    Arch Ophthalmol. 2007 Nov;125(11):1581-2. No abstract available. PMID: 17998528 [PubMed - indexed for MEDLINE]Related articles

    3.

    Diagnostic and therapeutic challenges.

    Reddy S, Slakter J, Aaberg TM Jr, Singh RP, Kaiser PK.

    Retina. 2007 Jun;27(5):642-7. No abstract available. PMID: 17558329 [PubMed - indexed for MEDLINE]Related articles

    4.

    [Retinopathy caused by desferrioxamine]

    Sánchez Dalmau BF, Vela Payán MD.

    Med Clin (Barc). 1996 Nov 9;107(16):636. Spanish. No abstract available. PMID: 9064398 [PubMed - indexed for MEDLINE]Related articles

    5.

    Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.

    Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ.

    J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):139-41.PMID: 9149744 [PubMed - indexed for MEDLINE]Related articles

    6.

    Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.

    Baath JS, Lam WC, Kirby M, Chun A.

    Retina. 2008 Jun;28(6):894-9.PMID: 18536609 [PubMed - indexed for MEDLINE]Related articles

    7.

    [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis]

    Spraul CW, Schicketanz C, Lang GE.

    Klin Monbl Augenheilkd. 1996 Jul;209(1):31-6. German. PMID: 8965474 [PubMed - indexed for MEDLINE]Related articles

    8.

    Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.

    Thio D, Prasad V, Anslow P, Lennox P.

    J Laryngol Otol. 2008 Nov;122(11):1253-6. Epub 2007 Oct 12.PMID: 17931455 [PubMed - indexed for MEDLINE]Related articles

    9.

    Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.

    Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M.

    Int J Hematol. 2007 Oct;86(3):212-5.PMID: 17988985 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Retinal pigment epithelium--desferal]

    Roulez F.

    Bull Soc Belge Ophtalmol. 2007;(304):59-66. Review. French. PMID: 17718228 [PubMed - indexed for MEDLINE]Related articles

    11.

    The expanded clinical spectrum of deferoxamine retinopathy.

    Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S; Deferoxamine Retinopathy Study Group.

    Ophthalmology. 2002 Jan;109(1):164-71.PMID: 11772599 [PubMed - indexed for MEDLINE]Related articles

    12.

    Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.

    Levin TL, Sheth S, Berdon WE, Ruzal-Shapiro C, Piomelli S.

    Pediatr Radiol. 1995 Nov;25 Suppl 1:S122-4.PMID: 8577502 [PubMed - indexed for MEDLINE]Related articles

    13.

    Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.

    Rego EM, Neto EB, Simões BP, Zago MA.

    Am J Hematol. 1998 Aug;58(4):340-1. No abstract available. PMID: 9692403 [PubMed - indexed for MEDLINE]Related articles

    14.

    Bilateral vitelliform maculopathy and deferoxamine toxicity.

    Gonzales CR, Lin AP, Engstrom RE, Kreiger AE.

    Retina. 2004 Jun;24(3):464-7. No abstract available. PMID: 15187676 [PubMed - indexed for MEDLINE]Related articles

    15.

    Severe infections in thalassaemic patients: prevalence and predisposing factors.

    Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A.

    Br J Haematol. 2006 Jun;133(6):667-74.PMID: 16704445 [PubMed - indexed for MEDLINE]Related articles

    16.

    Successful desensitization of a case with desferrioxamine hypersensitivity.

    Gülen F, Demir E, Tanaç R, Aydinok Y, Gulen H, Yenigün A, Can D.

    Minerva Pediatr. 2006 Dec;58(6):571-4.PMID: 17093379 [PubMed - indexed for MEDLINE]Related articles

    17.

    Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.

    Daar S, Pathare AV.

    Ann Hematol. 2006 May;85(5):315-9. Epub 2006 Feb 1.PMID: 16450126 [PubMed - indexed for MEDLINE]Related articles

    18.

    Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.

    Yarali N, Fişgin T, Duru F, Kara A, Ecin N, Fitoz S, Erden I.

    J Pediatr Hematol Oncol. 2006 Jan;28(1):11-6.PMID: 16394886 [PubMed - indexed for MEDLINE]Related articles

    19.

    Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

    Davis BA, Porter JB.

    Blood. 2000 Feb 15;95(4):1229-36.PMID: 10666195 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.

    Tam DH, Farber HW.

    Am J Hematol. 2006 Jun;81(6):443-7.PMID: 16680745 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity